dehydroxymethylepoxyquinomicin and Glomerulonephritis--Membranoproliferative

NF-kappaB participates in the transcriptional regulation of numerous genes, and many studies have confirmed the activation of NF-kappaB in inflammatory renal diseases. Therefore, NF-kappaB is a promising target for the treatment of these diseases. We tested the effects of dehydroxymethyl-epoxyquinomicin (DHMEQ), a novel NF-kappaB activation inhibitor, on anti-thy1.1 antibody-induced glomerulonephritis (Thy1.1 GN).. Thy1.1 GN was induced in Sprague-Dawley rats (6/group) by intravenous injection of anti-thy 1.1 antibody. The effects of DHMEQ (8 mg/kg/day) on the glomerular disease were evaluated using periodic acid-Schiff and Masson trichrome stains, immunohistochemistry for proliferating cell nuclear antigen, fibronectin and CD45 (leukocyte common antigen) and TUNEL staining. NF-kappaB activation was analyzed by a fluorescent electrophoretic mobility shift assay.. On day 7, DHMEQ treatment resulted in marked inhibition of NF-kappaB, decreased proteinuria (223.2 +/- 42.3 vs. 434.8 +/- 16.5 mg/kg/day, p < 0.05), preserved creatinine clearance (1.93 +/- 0.38 vs. 1.07 +/- 0.29 l/day, p < 0.01), decreased glomerular cell proliferation (15.8 +/- 1.2 vs. 31.2 +/- 0.8 nuclei/glomerular cross-section) and mesangial matrix deposition, and an increase in glomerular and tubular apoptosis without inducing any obvious adverse effects.. DHMEQ inhibited NF-kappaB and thereby suppressed the inflammatory renal responses in rats with Thy1.1 GN.

Topics: Animals; Antibodies; Benzamides; Cell Proliferation; Cyclohexanones; Glomerulonephritis, Membranoproliferative; Kidney Glomerulus; NF-kappa B; Rats; Thy-1 Antigens